Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States.
J Biomed Opt. 2017 Apr 1;22(4):40501. doi: 10.1117/1.JBO.22.4.040501.
Although the development of tumor-targeted fluorescent probes is a major area of investigation, it will be several years before these probes are realized for clinical use. Here, we report an approach that employs indocyanine-green (ICG), a clinically approved, nontargeted dye, in conjunction with fluorescence lifetime (FLT) detection to provide high accuracy for tumor-tissue identification in mouse models of subcutaneous human breast and brain tmors. The improved performance relies on the distinct FLTs of ICG within tumors versus tissue autofluorescence and is further aided by the well-known enhanced permeability and retention of ICG in tumors and the clearance of ICG from normal tissue several hours after intravenous injection. We demonstrate that FLT detection can provide more than 98% sensitivity and specificity, and a 10-fold reduction in error rates compared to intensity-based detection. Our studies suggest the significant potential of FLT-contrast for accurate tumor-tissue identification using ICG and other targeted probes under development, both for intraoperative imaging and for ex-vivo margin assessment of surgical specimens.
尽管肿瘤靶向荧光探针的开发是一个主要的研究领域,但这些探针要实现临床应用还需要几年的时间。在这里,我们报告了一种方法,该方法结合使用临床批准的非靶向染料吲哚菁绿(ICG)和荧光寿命(FLT)检测,以提供在皮下人乳腺癌和脑肿瘤小鼠模型中进行肿瘤组织识别的高度准确性。这种改进的性能依赖于肿瘤内与组织自发荧光之间 ICG 的独特 FLT,并且进一步得益于 ICG 在肿瘤中的通透性和保留增强以及静脉注射后数小时内 ICG 从正常组织中的清除。我们证明,与基于强度的检测相比,FLT 检测可提供超过 98%的灵敏度和特异性,并将错误率降低 10 倍。我们的研究表明,FLT 对比使用 ICG 和其他正在开发的靶向探针进行准确的肿瘤组织识别具有重要的潜力,无论是用于术中成像还是用于手术标本的离体边缘评估。